Hemoglobin disorders and endothelial cell interactions

Clinical Biochemistry

Volumn 42, Issue 18, 2009, Pages 1824-1838

  Conran, Nicola ^a   Costa, Fernando F ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Endothelial cells; Inflammation; Pathophysiology; Sickle cell disease; Thalassemia; Vaso occlusion

Indexed keywords

CD36 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PHOSPHATIDYLSERINE; PROTEOHEPARAN SULFATE; VASCULAR CELL ADHESION MOLECULE 1;

BLOOD VESSEL OCCLUSION; CELL ACTIVATION; CELL ADHESION; CELL FUNCTION; CELL INTERACTION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ERYTHROCYTE; HEMOGLOBINOPATHY; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; LEUKOCYTE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SICKLE CELL; SICKLE CELL ANEMIA; SPLEEN DEFECT; THALASSEMIA; THROMBOCYTE;

ANIMALS; CELL COMMUNICATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HEMOGLOBINOPATHIES; HUMANS; SPLEEN;

EID: 70449726798     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.06.024     Document Type: Review

References (200)

1. Galley H.F., and Webster N.R. Physiology of the endothelium. Br. J. Anaesth. 93 (2004) 105-113
2. Hartge M.M., Unger T., and Kintscher U. The endothelium and vascular inflammation in diabetes. Diab. Vasc. Dis. Res. 4 (2007) 84-88
3. Steinberg M.H. Management of sickle cell disease. N. Engl. J. Med. 340 (1999) 1021-1030
4. Madigan C., and Malik P. Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease. Expert. Rev. Mol. Med. 8 (2006) 1-23
5. Conran N., Franco-Penteado C.F., and Costa F.F. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin 33 (2009) 1-16
6. Huang A.L., and Vita J.A. Effects of systemic inflammation on endothelium-dependent vasodilation. Trends Cardiovasc. Med. 16 (2006) 15-20
7. Reiter C.D., and Gladwin M.T. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr. Opin. Hematol. 10 (2003) 99-107
8. Hsu L.L., Champion H.C., Campbell-Lee S.A., et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109 (2007) 3088-3098
9. Kaul D.K., Liu X.D., Chang H.Y., Nagel R.L., and Fabry M.E. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J. Clin. Invest. 114 (2004) 1136-1145
10. Lanaro C., Franco-Penteado C.F., Albuqueque D.M., Saad S.T., Conran N., and Costa F.F. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J. Leukoc. Biol. 85 (2009) 235-242
11. Graido-Gonzalez E., Doherty J.C., Bergreen E.W., Organ G., Telfer M., and McMillen M.A. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 92 (1998) 2551-2555
12. Buchanan G.R., and Holtkamp C.A. Plasma levels of platelet and vascular prostaglandin derivatives in children with sickle cell anaemia. Thromb. Haemost. 54 (1985) 394-396
13. Rybicki A.C., and Benjamin L.J. Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood 92 (1998) 2594-2596
14. Ergul S., Brunson C.Y., Hutchinson J., et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am. J. Hematol. 76 (2004) 245-251
15. Werdehoff S.G., Moore R.B., Hoff C.J., Fillingim E., and Hackman A.M. Elevated plasma endothelin-1 levels in sickle cell anemia: relationships to oxygen saturation and left ventricular hypertrophy. Am. J. Hematol. 58 (1998) 195-199
16. Phelan M., Perrine S.P., Brauer M., and Faller D.V. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J. Clin. Invest. 96 (1995) 1145-1151
17. Shiu Y.T., McIntire L.V., and Udden M.M. Sickle erythrocytes increase prostacyclin and endothelin-1 production by cultured human endothelial cells under flow conditions. Eur. J. Haematol. 68 (2002) 163-169
18. Makis A.C., Hatzimichael E.C., Kolios G., and Bourantas K.L. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment. Haematologica 89 (2004) 360-361
19. de Franceschi L., Baron A., Scarpa A., et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood 102 (2003) 1087-1096
20. Raij L. Nitric oxide and cardiovascular and renal effects. Osteoarthritis Cartilage 16 Suppl 2 (2008) S21-S26
21. Stuart M.J., and Nagel R.L. Sickle-cell disease. Lancet 364 (2004) 1343-1360
22. van Gils J.M., Zwaginga J.J., and Hordijk P.L. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J. Leukoc. Biol. 85 (2009) 195-204
23. Shiu Y.T., Udden M.M., and McIntire L.V. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 95 (2000) 3232-3241
24. Zennadi R., Chien A., Xu K., Batchvarova M., and Telen M.J. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 112 (2008) 3474-3483
25. Hebbel R.P., Yamada O., Moldow C.F., Jacob H.S., White J.G., and Eaton J.W. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J. Clin. Invest. 65 (1980) 154-160
26. Hebbel R.P. Adhesion of sickle red cells to endothelium: myths and future directions. Transfus. Clin. Biol. 15 (2008) 14-18
27. El Nemer W., Gauthier E., Wautier M.P., et al. Role of Lu/BCAM in abnormal adhesion of sickle red blood cells to vascular endothelium. Transfus. Clin. Biol. 15 (2008) 29-33
28. Kaul D.K., Tsai H.M., Liu X.D., Nakada M.T., Nagel R.L., and Coller B.S. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 95 (2000) 368-374
29. Matsui N.M., Borsig L., Rosen S.D., Yaghmai M., Varki A., and Embury S.H. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood 98 (2001) 1955-1962
30. Setty B.N., and Betal S.G. Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes. Blood 111 (2008) 905-914
31. Solovey A.A., Solovey A.N., Harkness J., and Hebbel R.P. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 97 (2001) 1937-1941
32. Wagner M.C., Eckman J.R., and Wick T.M. Histamine increases sickle erythrocyte adherence to endothelium. Br. J. Haematol. 132 (2006) 512-522
33. Wagner M.C., Eckman J.R., and Wick T.M. Sickle cell adhesion depends on hemodynamics and endothelial activation. J. Lab. Clin. Med. 144 (2004) 260-267
34. Barabino G.A., McIntire L.V., Eskin S.G., Sears D.A., and Udden M. Endothelial cell interactions with sickle cell, sickle trait, mechanically injured, and normal erythrocytes under controlled flow. Blood 70 (1987) 152-157
35. Kaul D.K., Finnegan E., and Barabino G.A. Sickle red cell-endothelium interactions. Microcirculation 16 (2009) 97-111
36. Covas D.T., de Lucena Angulo I., Vianna Bonini Palma P., and Zago M.A. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. Haematologica 89 (2004) 273-280
37. Gambero S., Canalli A.A., Traina F., et al. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. Eur. J. Haematol. 78 (2007) 144-151
38. Murphy M.M., Zayed M.A., Evans A., et al. Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LU. Blood 105 (2005) 3322-3329
39. Zennadi R., Hines P.C., De Castro L.M., Cartron J.P., Parise L.V., and Telen M.J. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood 104 (2004) 3774-3781
40. Manodori A.B., Barabino G.A., Lubin B.H., and Kuypers F.A. Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin. Blood 95 (2000) 1293-1300
41. Guchhait P., Dasgupta S.K., Le A., Yellapragada S., Lopez J.A., and Thiagarajan P. Lactadherin mediates sickle cell adhesion to vascular endothelial cells in flowing blood. Haematologica 92 (2007) 1266-1267
42. Embury S.H., Matsui N.M., Ramanujam S., et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood 104 (2004) 3378-3385
43. Brittain J.E., Knoll C.M., Ataga K.I., Orringer E.P., and Parise L.V. Fibronectin bridges monocytes and reticulocytes via integrin alpha4beta1. Br. J. Haematol. 141 (2008) 872-881
44. Finnegan E.M., Turhan A., Golan D.E., and Barabino G.A. Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion. Am. J. Hematol. 82 (2007) 266-275
45. Turhan A., Weiss L.A., Mohandas N., Coller B.S., and Frenette P.S. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proce. Natl. Acad. Sci. U.S.A. 99 (2002) 3047-3051
46. Haynes Jr. J., Obiako B., King J.A., Hester R.B., and Ofori-Acquah S. Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H1679-H1685
47. Turhan A., Jenab P., Bruhns P., Ravetch J.V., Coller B.S., and Frenette P.S. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 103 (2004) 2397-2400
48. Conran N., Almeida C.B., Lanaro C., et al. Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-protein kinase A dependent pathway in neutrophils from sickle cell disease patients. Br. J. Haematol. 139 (2007) 148-158
49. Conran N., Saad S.T., Costa F.F., and Ikuta T. Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease. Ann. Hematol. 86 (2007) 255-261
50. Castro O., Brambilla D.J., Thorington B., et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 84 (1994) 643-649
51. Kinney T.R., Sleeper L.A., Wang W.C., et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 103 (1999) 640-645
52. Miller S.T., Sleeper L.A., Pegelow C.H., et al. Prediction of adverse outcomes in children with sickle cell disease. N. Engl. J. Med. 342 (2000) 83-89
53. Frenette P.S. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr. Opin. Hematol. 9 (2002) 101-106
54. Fadlon E., Vordermeier S., Pearson T.C., et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 91 (1998) 266-274
55. Kasschau M.R., Barabino G.A., Bridges K.R., and Golan D.E. Adhesion of sickle neutrophils and erythrocytes to fibronectin. Blood 87 (1996) 771-780
56. Assis A., Conran N., Canalli A.A., Lorand-Metze I., Saad S.T., and Costa F.F. Effect of cytokines and chemokines on sickle neutrophil adhesion to fibronectin. Acta Haematol. 113 (2005) 130-136
57. Benkerrou M., Delarche C., Brahimi L., et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 99 (2002) 2297-2303
58. Canalli A.A., Ferreira R.P., Saad S.T.O., Conran N., and Costa F.F. The Adhesion of Sickle Cell Disease Neutrophils to Endothelial Layers, In Vitro, Is Mediated by the Mac-1, LFA-1 and VLA-4 Integrins. Blood 110 (2007) 2264
59. Conran N., Gambero A., Ferreira H.H., Antunes E., and de Nucci G. Nitric oxide has a role in regulating VLA-4-integrin expression on the human neutrophil cell surface. Biochem. Pharmacol. 66 (2003) 43-50
60. Ibbotson G.C., Doig C., Kaur J., et al. Functional alpha4-integrin: a newly identified pathway of neutrophil recruitment in critically ill septic patients. Nat. Med. 7 (2001) 465-470
61. Hidalgo A., Chang J., Jang J.E., Peired A.J., Chiang E.Y., and Frenette P.S. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat. Med. 15 (2009) 384-391
62. Chang J., Shi P.A., Chiang E.Y., and Frenette P.S. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 111 (2008) 915-923
63. Canalli A.A., Franco-Penteado C.F., Traina F., Saad S.T., Costa F.F., and Conran N. Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease. Eur. J. Haematol. 79 (2007) 330-337
64. Stenmark K.R., Davie N.J., Reeves J.T., and Frid M.G. Hypoxia, leukocytes, and the pulmonary circulation. J. Appl. Physiol. 98 (2005) 715-721
65. Kuebler W.M. Inflammatory pathways and microvascular responses in the lung. Pharmacol. Rep. 57 Suppl (2005) 196-205
66. Serjeant G.R., Serjeant B.E., Mohan J.S., and Clare A. Leg ulceration in sickle cell disease: medieval medicine in a modern world. Hematol. Oncol. Clin. North. Am. 19 (2005) 943-956 viii-ix
67. Smith P.C. The causes of skin damage and leg ulceration in chronic venous disease. Int. J. Low. Extrem. Wounds 5 (2006) 160-168
68. Villagra J., Shiva S., Hunter L.A., Machado R.F., Gladwin M.T., and Kato G.J. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 110 (2007) 2166-2172
69. Wun T., Paglieroni T., Rangaswami A., et al. Platelet activation in patients with sickle cell disease. Br. J. Haematol. 100 (1998) 741-749
70. Tomer A., Harker L.A., Kasey S., and Eckman J.R. Thrombogenesis in sickle cell disease. J. Lab. Clin. Med. 137 (2001) 398-407
71. Ferreira R.P., Franco-Penteado C.F., Saad S.T.O., Costa F.F., and Conran N. Platelets from sickle cell disease individuals demonstrate increased adhesive properties that are reversed by hydroxyurea therapy in association with alterations in intraplatelet cAMP and GPIIb/IIIa integrin activation. Blood 112 (2008) 2472
72. Ruggeri Z.M. Platelet adhesion under flow. Microcirculation 16 (2009) 58-83
73. Wun T., Paglieroni T., Field C.L., et al. Platelet-erythrocyte adhesion in sickle cell disease. J. Investig. Med. 47 (1999) 121-127
74. Lee S.P., Ataga K.I., Orringer E.P., Phillips D.R., and Parise L.V. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1626-1631
75. Kaul D.K., and Hebbel R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J. Clin. Invest. 106 (2000) 411-420
76. Aslan M., Ryan T.M., Townes T.M., et al. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J. Biol. Chem. 278 (2003) 4194-4204
77. Osarogiagbon U.R., Choong S., Belcher J.D., Vercellotti G.M., Paller M.S., and Hebbel R.P. Reperfusion injury pathophysiology in sickle transgenic mice. Blood 96 (2000) 314-320
78. Nath K.A., Grande J.P., Croatt A.J., et al. Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am. J. Pathol. 166 (2005) 963-972
79. Paffen E., and DeMaat M.P. C-reactive protein in atherosclerosis: a causal factor?. Cardiovasc. Res. 71 (2006) 30-39
80. Aslan M., Ryan T.M., Adler B., et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15215-15220
81. Wood K.C., and Granger D.N. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin. Exp. Pharmacol. Physiol. 34 (2007) 926-932
82. Wood K.C., Hebbel R.P., and Granger D.N. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J. 19 (2005) 989-991
83. Hebbel R.P., Eaton J.W., Balasingam M., and Steinberg M.H. Spontaneous oxygen radical generation by sickle erythrocytes. J. Clin. Invest. 70 (1982) 1253-1259
84. Xia Y., Dawson V.L., Dawson T.M., Snyder S.H., and Zweier J.L. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 6770-6774
85. Amer J., Ghoti H., Rachmilewitz E., Koren A., Levin C., and Fibach E. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br. J. Haematol. 132 (2006) 108-113
86. Natta C.L., Chen L.C., and Chow C.K. Selenium and glutathione peroxidase levels in sickle cell anemia. Acta Haematol. 83 (1990) 130-132
87. Schacter L., Warth J.A., Gordon E.M., Prasad A., and Klein B.L. Altered amount and activity of superoxide dismutase in sickle cell anemia. FASEB J. 2 (1988) 237-243
88. Kuypers F.A., Scott M.D., Schott M.A., Lubin B., and Chiu D.T. Use of ektacytometry to determine red cell susceptibility to oxidative stress. J. Lab. Clin. Med. 116 (1990) 535-545
89. Kaul D.K., Liu X.D., Choong S., Belcher J.D., Vercellotti G.M., and Hebbel R.P. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H293-H301
90. Sultana C., Shen Y., Rattan V., Johnson C., and Kalra V.K. Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood 92 (1998) 3924-3935
91. Iyamu E.W., Perdew H., and Woods G.M. Cysteine-iron promotes arginase activity by driving the Fenton reaction. Biochem. Biophys. Res. Commun. 376 (2008) 116-120
92. Thomas S.R., Witting P.K., and Drummond G.R. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 10 (2008) 1713-1765
93. Belcher J.D., Mahaseth H., Welch T.E., Otterbein L.E., Hebbel R.P., and Vercellotti G.M. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J. Clin. Invest. 116 (2006) 808-816
94. Lee M.Y., and Griendling K.K. Redox signaling, vascular function, and hypertension. Antioxid. Redox Signal. 10 (2008) 1045-1059
95. Radi R., Beckman J.S., Bush K.M., and Freeman B.A. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. 288 (1991) 481-487
96. Yasin Z., Witting S., Palascak M.B., Joiner C.H., Rucknagel D.L., and Franco R.S. Phosphatidylserine externalization in sickle red blood cells: associations with cell age, density, and hemoglobin F. Blood 102 (2003) 365-370
97. Natarajan M., Udden M.M., and McIntire L.V. Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro. Blood 87 (1996) 4845-4852
98. Setty B.N., Betal S.G., Zhang J., and Stuart M.J. Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J. Thromb. Haemost. 6 (2008) 2202-2209
99. Belcher J.D., Mahaseth H., Welch T.E., et al. Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H2715-H2725
100. Belcher J.D., Marker P.H., Weber J.P., Hebbel R.P., and Vercellotti G.M. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 96 (2000) 2451-2459
101. Kim K.S., Rajagopal V., Gonsalves C., Johnson C., and Kalra V.K. A novel role of hypoxia-inducible factor in cobalt chloride- and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells. J. Immunol. 177 (2006) 7211-7224
102. Croizat H. Circulating cytokines in sickle cell patients during steady state. Br. J. Haematol. 87 (1994) 592-597
103. Francis Jr. R.B., and Haywood L.J. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J. Natl. Med. Assoc. 84 (1992) 611-615
104. Goncalves M.S., Queiroz I.L., Cardoso S.A., et al. Interleukin 8 as a vaso-occlusive marker in Brazilian patients with sickle cell disease. Braz. J. Med. Biol. Res. 34 (2001) 1309-1313
105. Hibbert J.M., Hsu L.L., Bhathena S.J., et al. Proinflammatory cytokines and the hypermetabolism of children with sickle cell disease. Exp. Biol. Med. 230 (2005) 68-74
106. Lam W.A., Hansen W.R., Huang J., et al. Aldosterone promotes inflammation and endothelial cell-sickle cell adhesion: potential for a new therapeutic target in sickle cell disease. Blood 112 (2008) 125
107. Solovey A., Lin Y., Browne P., Choong S., Wayner E., and Hebbel R.P. Circulating activated endothelial cells in sickle cell anemia. N. Engl. J. Med. 337 (1997) 1584-1590
108. Strijbos M.H., Landburg P.P., Nur E., et al. Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia?. Blood Cells Mol. Dis. 43 (2009) 63-67
109. Otterbein L.E., Soares M.P., Yamashita K., and Bach F.H. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 24 (2003) 449-455
110. Wagener F.A., Volk H.D., Willis D., et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol. Rev. 55 (2003) 551-571
111. Walter P.B., Fung E.B., Killilea D.W., et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br. J. Haematol. 135 (2006) 254-263
112. Thein S.L. Genetic modifiers of the beta-haemoglobinopathies. Br. J. Haematol. 141 (2008) 357-366
113. Taylor J.G.t., Tang D.C., Savage S.A., et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 100 (2002) 4303-4309
114. Hoppe C., Klitz W., D'Harlingue K., et al. Confirmation of an association between the TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke 38 (2007) 2241-2246
115. Sharan K., Surrey S., Ballas S., et al. Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br. J. Haematol. 124 (2004) 240-243
116. Chaar V., Tarer V., Etienne-Julan M., Diara J.P., Elion J., and Romana M. ET-1 and ecNOS gene polymorphisms and susceptibility to acute chest syndrome and painful vaso-occlusive crises in children with sickle cell anemia. Haematologica 91 (2006) 1277-1278
117. Baldwin C., Nolan V.G., Wyszynski D.F., et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood 106 (2005) 372-375
118. Sebastiani P., Ramoni M.F., Nolan V., Baldwin C.T., and Steinberg M.H. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat. Gen. 37 (2005) 435-440
119. Nolan V.G., Baldwin C., Ma Q., et al. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br. J. Haematol. 128 (2005) 266-272
120. Nolan V.G., Adewoye A., Baldwin C., et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br. J. Haematol. 133 (2006) 570-578
121. Eickelberg O., and Morty R.E. Transforming growth factor beta/bone morphogenic protein signaling in pulmonary arterial hypertension: remodeling revisited. Trends Cardiovasc. Med. 17 (2007) 263-269
122. Ashley-Koch A.E., Elliott L., Kail M.E., et al. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood 111 (2008) 5721-5726
123. Adewoye A.H., Nolan V.G., Ma Q., et al. Association of polymorphisms of IGF1R and genes in the transforming growth factor-beta/bone morphogenetic protein pathway with bacteremia in sickle cell anemia. Clin. Infect. Dis. 43 (2006) 593-598
124. Elliott L., Ashley-Koch A.E., De Castro L., et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br. J. Haematol. 137 (2007) 262-267
125. Brawley O.W., Cornelius L.J., Edwards L.R., et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann. Intern. Med. 148 (2008) 932-938
126. Charache S., Barton F.B., Moore R.D., et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine 75 (1996) 300-326
127. Cokic V.P., Smith R.D., Beleslin-Cokic B.B., et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J. Clin. Invest. 111 (2003) 231-239
128. Conran N., Oresco-Santos C., Acosta H.C., Fattori A., Saad S.T., and Costa F.F. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Br. J. Haematol. 124 (2004) 547-554
129. Huang J., Kim-Shapiro D.B., and King S.B. Catalase-mediated nitric oxide formation from hydroxyurea. J. Med. Chem. 47 (2004) 3495-3501
130. Ikuta T., Ausenda S., and Cappellini M.D. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1847-1852
131. King S.B. Nitric oxide production from hydroxyurea. Free Rad. Biol. Med. 37 (2004) 737-744
132. Cokic V.P., Andric S.A., Stojilkovic S.S., Noguchi C.T., and Schechter A.N. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 111 (2008) 1117-1123
133. Cokic V.P., Beleslin-Cokic B.B., Noguchi C.T., and Schechter A.N. Hydroxyurea increases eNOS protein levels through inhibition of proteasome activity. Nitric Oxide 16 (2007) 371-378
134. Conran N., Fattori A., Saad S.T., and Costa F.F. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. Am. J. Hematol. 76 (2004) 343-347
135. Kato G.J., Martyr S., Blackwelder W.C., et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br. J. Haematol. 130 (2005) 943-953
136. Saleh A.W., Hillen H.F., and Duits A.J. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta. Haematol. 102 (1999) 31-37
137. Brun M., Bourdoulous S., Couraud P.O., Elion J., Krishnamoorthy R., and Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J. 3 (2003) 215-226
138. Lapoumeroulie C., Benkerrou M., Odievre M.H., Ducrocq R., Brun M., and Elion J. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea. Haematologica 90 (2005) 401-403
139. Cartron J.P., and Elion J. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea. Transfus. Clin. Biol. 15 (2008) 39-50
140. Hankins J., and Aygun B. Pharmacotherapy in sickle cell disease - state of the art and future prospects. Br. J. Haematol. 145 (2009) 296-308
141. Steinberg M.H. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol. Sci. 27 (2006) 204-210
142. Weiner D.L., Hibberd P.L., Betit P., Cooper A.B., Botelho C.A., and Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 289 (2003) 1136-1142
143. Mack A.K., McGowan Ii V.R., Tremonti C.K., et al. Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. Br. J. Haematol. (2008)
144. Canalli A.A., Franco-Penteado C.F., Saad S.T.O., Conran N., and Costa F.F. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologia 93 (2008) 605-609
145. De Caterina R., Libby P., Peng H.B., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96 (1995) 60-68
146. Dasgupta T., Hebbel R.P., and Kaul D.K. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic. Biol. Med. 41 (2006) 1771-1780
147. Kato G.J., and Gladwin M.T. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 300 (2008) 2638-2646
148. Romero J.R., Suzuka S.M., Nagel R.L., and Fabry M.E. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood 99 (2002) 1103-1108
149. Little J.A., Hauser K.P., Martyr S.E., et al. Hematologic, biochemical, and cardiopulmonary effects of l-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur. J. Haematol. 82 (2009) 315-321
150. Katusic Z.S., d'Uscio L.V., and Nath K.A. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol. Sci. 30 (2009) 48-54
151. Suckling C.J., Gibson C.L., Huggan J.K., et al. 6-Acetyl-7,7-dimethyl-5,6,7,8-tetrahydropterin is an activator of nitric oxide synthases. Bioorg. Med. Chem. Lett. 18 (2008) 1563-1566
152. Mack A.K., and Kato G.J. Sickle cell disease and nitric oxide: a paradigm shift?. Int. J. Biochem. Cell. Biol. 38 (2006) 1237-1243
153. Bao B., Prasad A.S., Beck F.W., et al. Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. Transl. Res. 152 (2008) 67-80
154. Murad F. Cellular signaling with nitric oxide and cyclic GMP. Braz. J. Med. Biol. Res. 32 (1999) 1317-1327
155. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 (2006) 488-520
156. Machado R.F., Martyr S., Kato G.J., et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br. J. Haematol. 130 (2005) 445-453
157. Almeida C.B., Traina F., Lanaro C., et al. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils. Br. J. Haematol. 142 (2008) 836-844
158. De Franceschi L., Platt O.S., Malpeli G., et al. Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB J. 22 (2008) 1849-1860
159. Lima C.S., Ueti O.M., Ueti A.A., Franchini K.G., Costa F.F., and Saad S.T. Enalapril therapy and cardiac remodelling in sickle cell disease patients. Acta Cardiol. 63 (2008) 599-602
160. Sabaa N., de Franceschi L., Bonnin P., et al. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J. Clin. Invest. 118 (2008) 1924-1933
161. Lionnet F., Bachmeyer C., Stankovic K., Tharaux P.L., Girot R., and Aractingi S. Efficacy of the endothelin receptor blocker bosentan for refractory sickle cell leg ulcers. Br. J. Haematol. 142 (2008) 991-992
162. Kaul D.K., Kollander R., Mahaseth H., et al. Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation. Microcirculation 13 (2006) 489-497
163. Jasinska M., Owczarek J., and Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Rep. 59 (2007) 483-499
164. Solovey A., Kollander R., Shet A., et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 104 (2004) 840-846
165. Canalli A.A., Ferreira R.P., Saad S.T.O., Conran N., and Costa F.F. Simvastatin reduces the in vitro adhesion of sickle cell disease neutrophils to endothelial layers. Blood 112 (2008) 2489
166. Kaul D.K., Liu X.D., Zhang X., et al. Peptides based on alphaV-binding domains of erythrocyte ICAM-4 inhibit sickle red cell-endothelial interactions and vaso-occlusion in the microcirculation. Am. J. Physiol. Cell. Physiol. 291 (2006) C922-C930
167. Finnegan E.M., Barabino G.A., Liu X.D., Chang H.Y., Jonczyk A., and Kaul D.K. Small-molecule cyclic alpha V beta 3 antagonists inhibit sickle red cell adhesion to vascular endothelium and vasoocclusion. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H1038-H1045
168. Matsui N.M., Varki A., and Embury S.H. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 100 (2002) 3790-3796
169. Lee S.P., Ataga K.I., Zayed M., et al. Phase I study of eptifibatide in patients with sickle cell anaemia. Br. J. Haematol. 139 (2007) 612-620
170. Chang J., Patton J., Frenette P.S., and Magnani J.L. Effects of pan-selectin antagonist GMI-1070 on the treatment of vaso-occlusion in sickle cell mice. Blood 112 (2008) 535
171. Taher A.T., Otrock Z.K., Uthman I., and Cappellini M.D. Thalassemia and hypercoagulability. Blood Rev. 22 (2008) 283-292
172. Aggeli C., Antoniades C., Cosma C., et al. Endothelial dysfunction and inflammatory process in transfusion-dependent patients with beta-thalassemia major. Int. J. Cardiol. 105 (2005) 80-84
173. Butthep P., Bunyaratvej A., Funahara Y., et al. Alterations in vascular endothelial cell-related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb. Haemost. 74 (1995) 1045-1049
174. Butthep P., Rummavas S., Wisedpanichkij R., Jindadamrongwech S., Fucharoen S., and Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am. J. Hematol. 70 (2002) 100-106
175. Kyriakou D.S., Alexandrakis M.G., Kyriakou E.S., et al. Activated peripheral blood and endothelial cells in thalassemia patients. Ann. Hematol. 80 (2001) 577-583
176. Shitrit D., Tamary H., Koren A., et al. Correlation of vascular endothelial growth factor with the severity of thalassemia intermedia. Blood Coagul. Fibrinolysis 19 (2008) 611-614
177. Hovav T., Goldfarb A., Artmann G., Yedgar S., and Barshtein G. Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. Br. J. Haematol. 106 (1999) 178-181
178. Franco-Penteado C.F., Bezerra M.A.C., Mello M.R.B., et al. Increased adhesive properties and reactive oxygen species of red cells, platelets and leukocytes and neutrophil chemotaxis in IVS-1-6 (T C) homozygous beta-thalassemia intermedia. Blood 112 (2008) 1873
179. Eldor A., Durst R., Hy-Am E., et al. A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood. Br. J. Haematol. 107 (1999) 739-746
180. Ataga K.I., Cappellini M.D., and Rachmilewitz E.A. beta-Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br. J. Haematol. 139 (2007) 3-13
181. Habib A., Kunzelmann C., Shamseddeen W., Zobairi F., Freyssinet J.M., and Taher A. Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica 93 (2008) 941-942
182. WBeutlerajcman E. Hemoglobinopathies associated with unstable hemoglobin. In: Beutler E.L.M., Coller B.S., Kipps T.J., and Seligsohn U. (Eds). Williams Hematology. 6th Edition (2000), McGraw-Hill Professional 607-610
183. Wajcman H., Traeger-Synodinos J., Papassotiriou I., et al. Unstable and thalassemic alpha chain hemoglobin variants: a cause of Hb H disease and thalassemia intermedia. Hemoglobin 32 (2008) 327-349
184. Galacteros F., Girodon E., M'Rad A., et al. Hb Taybe (alpha 38 or 39 THR deleted): an alpha-globin defect, silent in the heterozygous state and producing severe hemolytic anemia in the homozygous. C. R. Acad. Sci. III 317 (1994) 437-444
185. Rahbar S., Feagler R.J., and Beutler E. Hemoglobin Hammersmith (beta 42 (CD1) Phe replaced by Ser) associated with severe hemolytic anemia. Hemoglobin 5 (1981) 97-105
186. Sonati M.F., Kimura E.M., Abreu C.F., Oliveira D.M., Pinheiro V.R., and Costa F.F. Hemoglobin Hammersmith [beta42 (CD1) Phe → Ser] in a Brazilian girl with congenital Heinz body hemolytic anemia. Pediatr. Blood Cancer. 47 (2006) 855-856 author reply 7-8
187. Atamna H., and Ginsburg H. Heme degradation in the presence of glutathione. A proposed mechanism to account for the high levels of non-heme iron found in the membranes of hemoglobinopathic red blood cells. J. Biol. Chem. 270 (1995) 24876-24883
188. Au N.H., Wong A.Y., Vickars L., MacGillivray R.T., and Wadsworth L.D. Two new examples of Hb St. Etienne [beta 92(F8)HisGln] in association with venous thrombosis. Hemoglobin 33 (2009) 95-100
189. Honig G.R., Telfer M.C., Rosenblum B.B., and Vida L.N. Hb Warsaw (beta 42 Phe---Val): an unstable hemoglobin with decreased oxygen affinity. I. Hematologic and clinical expression. Am. J. Hematol. 32 (1989) 36-41
190. Krishnan K., Martinez F., Wille R.T., et al. Hb Washtenaw [beta 11(A8)Val → Phe]: an electrophorectically silent, unstable, low oxygen affinity variant associated with anemia and chronic cyanosis. Hemoglobin 18 (1994) 285-295
191. Lode H.N., Krings G., Schulze-Neick I., et al. Pulmonary hypertension in a case of Hb-Mainz hemolytic anemia. J. Pediatr. Hematol. Oncol. 29 (2007) 173-177
192. Khatib R., Rabah R., and Sarnaik S.A. The spleen in the sickling disorders: an update. Pediatr. Radiol. 39 (2009) 17-22
193. de Chadarevian J.P., Balarezo F.S., Heggere M., and Dampier C. Splenic arteries and veins in pediatric sickle cell disease. Pediatr. Dev. Pathol. 4 (2001) 538-544
194. Hankins J.S., Helton K.J., McCarville M.B., Li C.S., Wang W.C., and Ware R.E. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr. Blood Cancer. 50 (2008) 293-297
195. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br. J. Haematol. 138 (2007) 291-304
196. Purcell P.L., Crary S.E., Adix L.M., Alder A.C., and Buchanan G.R. Postsplenectomy vascular complications: feasibility of studying patients with splenectomy following trauma. Am. J. Hematol. 84 (2009) 316-317
197. Cappellini M.D., Grespi E., Cassinerio E., Bignamini D., and Fiorelli G. Coagulation and splenectomy: an overview. Ann. N. Y. Acad. Sci. 1054 (2005) 317-324
198. Singer S.T., Kuypers F.A., Styles L., Vichinsky E.P., Foote D., and Rosenfeld H. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am. J. Hematol. 81 (2006) 670-675
199. Peacock A.J. Pulmonary hypertension after splenectomy: a consequence of loss of the splenic filter or is there something more?. Thorax 60 (2005) 983-984
200. Phrommintikul A., Sukonthasarn A., Kanjanavanit R., and Nawarawong W. Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart 92 (2006) 1467-1472